Viva Biotech Holdings 2024 SR
The report highlights Viva Biotech's transition to an AI-driven drug discovery platform and its steady growth in the CRO and CDMO sectors. In 2024, the company achieved a significant turnaround with a net profit of RMB 222.0 million. Key environmental milestones include Langhua Pharmaceutical's commitment to the Science Based Targets initiative (SBTi) and the first-time disclosure of Scope 3 emissions. The group also maintained a strong focus on responsible investment, with 93 portfolio companies and 41 pipelines in clinical stages. Socially, the company emphasized talent development and occupational health, achieving zero work-related fatalities.
Company: Viva Biotech Holdings
Sector: Health Care
Country: China
Year: 2024
Type: SR
Pages: 106
Viva Biotech Holdings
ESG Report
The report highlights Viva Biotech's transition to an AI-driven drug discovery platform and its steady growth in the CRO and CDMO sectors. In 2024, the company achieved a significant turnaround with a net profit of RMB 222.0 million. Key environmental milestones include Langhua Pharmaceutical's commitment to the Science Based Targets initiative (SBTi) and the first-time disclosure of Scope 3 emissions. The group also maintained a strong focus on responsible investment, with 93 portfolio companies and 41 pipelines in clinical stages. Socially, the company emphasized talent development and occupational health, achieving zero work-related fatalities.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Published
Apr 21, 2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Workplace Fatalities
Employees